RA
MDGL icon

Rise Advisors’s Madrigal Pharmaceuticals MDGL Stock Holding History

Rise Advisors’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-35
Closed -$16.1K – 894
2025
Q3 		$16.1K Hold
35
– – 0.01% 710
2025
Q2 		$10.6K Sell
35
-1
-3% -$298 ﹤0.01% 962
2025
Q1 		$11.9K Buy
+36
New +$11.8K 0.01% 848

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Rise Advisors's MDGL Position: Q4 2025 in Review

Rise Advisors sold out of Madrigal Pharmaceuticals (MDGL) in Q4 2025, closing a stake of 35 shares — an estimated $16.1K sold.

Rise Advisors first reported a position in MDGL in Q1 2025 and held it in 3 quarters. The position peaked at $16.1K in Q3 2025. 387 funds tracked by Wall St. Rank hold MDGL as of Q4 2025.

  • Rise Advisors reported no remaining Madrigal Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Rise Advisors sold 35 Madrigal Pharmaceuticals shares in Q4 2025, an estimated $16.1K.
  • Rise Advisors first reported a position in Madrigal Pharmaceuticals in Q1 2025 and held it in 3 quarters.
  • Rise Advisors's Madrigal Pharmaceuticals position peaked at $16.1K in Q3 2025.
  • 387 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q4 2025.

Based on Rise Advisors's 13F filing for Q4 2025, filed 11 Feb 2026.